Urology
Volume 73, Issue 2 , Pages 356-361 , February 2009

Absence of Relationship Between Steroid Hormone Levels and Prostate Cancer Tumor Grade

This study was first presented at the 2008 American Society for Clinical Oncology Genitourinary Cancers Symposium, February 14-16, 2008, San Francisco, California.

  • David J. Sher

      Affiliations

    • Harvard Radiation Oncology Program, Boston, Massachusetts
    • ,
  • Christos Mantzoros

      Affiliations

    • Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts
    • ,
  • Susanna Jacobus

      Affiliations

    • Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Meredith M. Regan

      Affiliations

    • Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Gwo-Shu Lee

      Affiliations

    • Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • William K. Oh

      Affiliations

    • Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • Corresponding Author InformationReprint requests: William K. Oh, M.D., Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115

Received 19 April 2008 ,Accepted 15 July 2008.

References 

  1. Huggins C, Stevens RE, Hodges CV. Studies on prostatic cancer (II. The effects of castration on advanced carcinoma of the prostate gland). Arch Surg. 1941;43:209–223
  2. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360:103–106
  3. Messing EM, Manola J, Sarosdy M, et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999;341:1781–1788
  4. Pilepich MV, Caplan R, Byhardt RW, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group protocol 85-31. J Clin Oncol. 1997;15:1013–1021
  5. Schatzl G, Madersbacher S, Thurridl T, et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate. 2001;47:52–58
  6. Hoffman MA, DeWolf WC, Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer?. J Urol. 2000;163:824–827
  7. Fodstad P, Bjoro T, Torlakovic G, et al. No association of serum gonadal or pituitary hormones with prognostic parameters in stages T1 to T3 PN0M0 prostate cancer. J Urol. 2002;168:1188–1192
  8. Platz EA, Leitzmann MF, Rifai N, et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev. 2005;14:1262–1269
  9. Oh WK, Hayes J, Evan C, et al. Development of an integrated prostate cancer research information system. Clin Genitourin Cancer. 2006;5:61–66
  10. Amling CL, Riffenburgh RH, Sun L, et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol. 2004;22:439–445
  11. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006;98:529–534
  12. Brawley OW, Ford LG, Thompson I, et al. 5-Alpha-reductase inhibition and prostate cancer prevention. Cancer Epidemiol Biomarkers Prev. 1994;3:177–182
  13. Nishiyama T, Ikarashi T, Hashimoto Y, et al. Association between the dihydrotestosterone level in the prostate and prostate cancer aggressiveness using the Gleason score. J Urol. 2006;176:1387–1391
  14. Travis RC, Key TJ, Allen NE, et al. Serum androgens and prostate cancer among 643 cases and 643 controls in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2007;121:1331–1338
  15. Chen C, Weiss NS, Stanczyk FZ, et al. Endogenous sex hormones and prostate cancer risk: a case-control study nested within the carotene and retinol efficacy trial. Cancer Epidemiol Biomarkers Prev. 2003;12:1410–1416
  16. Crawford ED, Barqawi AB, O'Donnell C, et al. The association of time of day and serum testosterone concentration in a large screening population. BJU Int. 2007;100:509–513

 This study was supported by the Bing Sound Wong Fund for Prostate Cancer Research and Louis DiGiovanni Fund (both to W. K. Oh).

PII: S0090-4295(08)01562-8

doi: 10.1016/j.urology.2008.07.068

Urology
Volume 73, Issue 2 , Pages 356-361 , February 2009

Article Tools